ArticleJournal of cheminformatics2026
A pipeline for developing AI-driven models to predict molecular initiating events: a case study on neural tube defects.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Adverse Outcome Pathways (AOPs) describe the sequence of molecular and cellular events that lead to toxicity. Each pathway begins with a Molecular Initiating Event (MIE) and ends in an Adverse Outcome. Early identification of chemical activity on MIE-relevant protein targets supports first-line toxicity assessment and helps researchers prioritize mechanisms for subsequent experimental investigation. Here we present an automated AI pipeline that converts raw ChEMBL bioactivity data into optimized deep learning models for MIE prediction. The pipeline builds on the Knowledge-Guided Pre-training of Graph Transformer (KPGT) framework, which represents chemical structures as knowledge-enriched molecular graphs. It integrates data curation, molecular graph generation, and model training and tuning. This integration enables users to construct target-specific prediction models in a seamless and reproducible way, starting from initial data and ending with deployable AI. We demonstrate its use in a neural tube defect (NTD) case study, where fine-tuned KPGT models outperformed traditional Support Vector Machine models with a radial basis function kernel (SVM-RBF) when predicting MIEs linked to developmental toxicity. The results highlight the potential of AI-driven toxicity modeling to accelerate AOP development, improve endpoint prioritization, and prioritize chemicals for experimental follow-up. By providing an end-to-end, data-to-model workflow, the pipeline lowers the technical barrier to using modern graph-based neural architectures in toxicology. It offers a reproducible route to deployable MIE prediction models that support AOP development, compound prioritization, and early-stage chemical safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.